We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+32.15%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.4B
AUM Growth
+$519M
(+28%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
4.53%
Top 10 Holdings %
Top 10 Hldgs %
68.89%
Holding
38
New
2
Increased
14
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AIMT
Aimmune Therapeutics
AIMT
|
+$55.6M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$20.5M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$19.3M |
| 4 |
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
|
+$11.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$7.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$23.3M |
| 2 |
SHPG
Shire pic
SHPG
|
+$8.34M |
| 3 |
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
|
+$5 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$168B
| $11.4M | 0.48% |
175,900
| – | – |
|
27
Rigel Pharmaceuticals
RIGL
$782M
| $10.2M | 0.43% |
398,595
| – | – |
|
|
DRNA
28
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $7.34M | 0.31% |
500,913
| – | – |
|
|
ALIM
29
DELISTED
Alimera Sciences
ALIM
| $3.19M | 0.13% |
200,920
| – | – |
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $1.62M | 0.07% |
29,500
| – | – |
|
|
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $1.41M | 0.06% |
33,214
| – | – |
|
32
Cytokinetics
CYTK
$10.5B
| $1M | 0.04% |
123,686
| – | – |
|
|
MRNS
33
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $477K | 0.02% |
+28,555
| New | +$411K |
|
|
SPHS
34
DELISTED
Sophiris Bio, Inc.
SPHS
| $245K | 0.01% |
247,000
| – | – |
|
|
ACGN
35
DELISTED
Aceragen Inc
ACGN
| $196K | 0.01% |
4,537
| – | – |
|
|
MLNT
36
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $36K | ﹤0.01% |
10,137
-1
| -0% | -$5 |
|
37
Ocugen
OCGN
$475M
| $35K | ﹤0.01% |
5,049
| – | – |
|
|
SHPG
38
DELISTED
Shire pic
SHPG
| – | – |
-47,938
| Closed | -$8.34M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q1 2019 Portfolio in Review
As of Q1 2019, Palo Alto Investors held 38 positions worth $2.4B, up 28% from $1.88B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Palo Alto Investors deployed $109M of net new capital in Q1 2019, opening 2 new positions and adding to 14 existing holdings. Its largest new stake was Kaleido Biosciences, Inc. Common Stock: 866,666 shares worth $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier.
On the sell side, the largest reduction was Celgene Corp, an estimated $23.3M trimmed.
- Palo Alto Investors's largest Q1 2019 buy was Kaleido Biosciences, Inc. Common Stock: 866,666 shares worth $12.6M.
- Palo Alto Investors added most to Aimmune Therapeutics in Q1 2019, an estimated $55.6M increase.
- Palo Alto Investors's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $23.3M.
- Palo Alto Investors fully exited Shire pic in Q1 2019, selling an estimated $8.34M.
- Palo Alto Investors's ten largest holdings make up 69% of its $2.4B portfolio in Q1 2019.
- Palo Alto Investors opened 2 new positions and closed 1 in Q1 2019.
- Palo Alto Investors's portfolio value rose 28% quarter-over-quarter to $2.4B.
Based on Palo Alto Investors's 13F filing for Q1 2019, filed 15 May 2019.